Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1997-07-10
2004-08-31
Priebe, Scott D. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200, C424S093210
Reexamination Certificate
active
06784162
ABSTRACT:
BACKGROUND OF THE INVENTION
This application relates to a method, reagent and kit for evaluating susceptibility to and causation of premature atherosclerosis and other forms of coronary artery disease. The invention further relates to a method of gene therapy by which lipoprotein lipase deficiencies can be treated, and to transducing vectors for use in such a method.
“Coronary artery disease” is a collective term for a variety of symptomatic conditions including angina, myocardial infarction, and nonspecific chest, arm and face pain, which result from atherosclerosis of the arteries that supply blood to the heart. Atherosclerosis, commonly known as “hardening of the arteries” is caused by the formation of deposits of fatty substances such as cholesterol within the inner layers or endothelium of the arteries.
“Premature atherosclerosis” as used herein refers to the clinical presentation of signs and symptoms of coronary artery disease before the age of 65.
Because of the significant relationship between coronary artery disease and heart attacks, considerable effort has been devoted to identifying the biochemical causes of atherosclerosis. This research has shown that high levels of total cholesterol, low density lipoprotein (LDL), very low density lipoprotein (VLDL) and triglycerides are associated with increased risk of coronary artery disease, while high levels of high density lipoproteins (HDL) are associated with decreased risk of coronary artery disease. See. Gordon et al.,
The Amer. J. Med
. 62: 707-714 (1977). However, while observation of lipoproteins, cholesterol and triglycerides can provide a basis for identifying individuals at risk of coronary artery disease, the levels of these substances are themselves symptoms of an underlying biochemical defect which remains unidentified. Thus, specific treatment of the ultimate cause rather than an intermediate condition, and prediction of risk prior to the onset of this intermediate condition is not possible through such observation.
Studies directed towards the underlying cause of coronary artery disease have identified a number of mutations in genes coding for proteins involved in lipid transport and metabolism that appear to be associated with an increased risk. Examples include a large number of mutations in the low-density lipoprotein receptor gene, Hobbs et al.,
Human Mutations
1: 445-466 (1992), and a single mutation in the apolipoprotein-B (Apo-B) gene which underlies familial defective Apo-B in many parts of the world. Soria et al.,
Proc. Nat'l Acad. Sci. USA
86: 587-91 (1989). In addition, mutations in other genes which play a significant role in HDL metabolism such as the cholesterol ester transferase protein (CETP) gene, Brown et al.,
Nature
342: 448-451 (1989) and the gene for Apo-A1, Rubin et al.,
Nature
353: 265-266 (1991), have also been shown to be associated with either enhanced resistance or increased susceptibility to atherosclerosis. However, these mutations are uncommon and thus far no specific mutation in any gene has been found in a significant number (i.e., >1%) of patients with coronary artery disease or premature atherosclerosis. Accordingly, these test results while interesting do not offer the opportunity to provide evaluation or therapy to significant numbers of patients
SUMMARY OF THE INVENTION
It has now been found that a single point mutation in the human lipoprotein lipase gene which results in an A→G nucleotide change at codon 291 (nucleotide 1127) of the lipoprotein lipase gene, and a substitution of serine for the normal asparagine in the lipoprotein lipase gene product is seen with increased frequency in patients with coronary artery disease, and is associated with an increased susceptibility to coronary artery disease, including in particular premature atherosclerosis. This is expressed as a diminished catalytic activity of lipoprotein lipase, lower HDL-cholesterol levels and higher triglyceride levels. Thus, in accordance with the present invention there is provided a method for evaluating susceptibility of a human individual to premature atherosclerosis and other forms of coronary artery disease comprising the steps of:
(a) obtaining a sample of DNA from the individual; and
(b) evaluating the sample of DNA for the presence of nucleotides encoding a serine residue as amino acid 291 of the lipoprotein lipase gene product. The presence of a serine residue is indicative of increased susceptibility in the patient.
The invention further provides a kit for performing the method of the invention. Such a kit comprises a pair of primers selected to amplify a region of a human lipoprotein lipase gene spanning amino acid 291 of human lipoprotein lipase. Appropriate additional reagents may also be included in the kit such as polymerase enzymes, nucleoside stock solutions and the like.
A further aspect of the present invention is a method of treating patients suffering from or likely to suffer from premature atherosclerosis and other forms of coronary artery disease as a result of a lipoprotein lipase deficiency using gene therapy. This may be accomplished using adenovirus-mediated or retrovirus-mediated gene therapy, and can be performed using either an in vivo or an ex vivo approach.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4957858 (1990-09-01), Chu et al.
patent: 5124246 (1992-06-01), Urdea et al.
patent: 5200314 (1993-04-01), Urdea
patent: 5270184 (1993-12-01), Walker et al.
patent: 0497272 (1992-08-01), None
patent: 2202328 (1988-09-01), None
patent: WO-89/09284 (1989-10-01), None
patent: WO9533840 (1995-12-01), None
Verma et al., “Gene therapy—promises, problems and prospects”, Nature 389: 239-242, Sep. 1997.*
Orkin et al. “Report and recommendations of the panel to asses the NIH investment in research on gene therapy”, issued by the U.S. National Institutes of Health, Dec. 1995.*
Galton et al., “Polymorphisms of the lipoprotein lipase gene and premature atherosclerosis”,J. Int. Med.236:63-68 (1994).
Hayden et al., “Phenotypic variation in mutations in the human lipoprotein lipase gene”,Biochem. Soc. Trans.21: 506-509 (1993).
Deeb et al., “Mutations in the Lipoprotein Lipase Gene in Familial Combined Hyperlipidemia and Coronary Artery Disease”,Circulation92: Abst 2351 (1995).
Tsutsumi et al., “The Novel Compound NO-1886 Increase Lipoproteim Lipase Activity with Resultimg Elevation of High Density Lipoprotein Cholesterol, and Long-term Administration Inhibits Atherogenesis in the Coronary Arteries of Rats with Experimental Atherosclerosis”,J. Clin. Invest.92: 411-417 (1992).
Kuusi et al., “Postheparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyperalphalipoproteinemia”, J. Lipid Research 30: 1117-1125 (1989).
Taskinen et al., “High Density lipoprotein subfractions in relation to lipoportein lipase acticity of tissues in man—evidence of reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipase”,Clinica Chimica Acta112: 325-332 (1981).
Zilversmit, D.B., “A Proposal Linking Atherogenesis to the Interaction of Endothelial Lipoprotein LIpase with Triglyceride-Rich Lipoproteins”,Circulation Research33: 633-638 (1973).
Hayden et al., “Molecular genetics of Human Lipoprotein Lipase Deficiency”,Molecular and Cellualr Biochemistry113: 171-176 (1992).
Ma et al., “High Frequency of Mutation in the Human Lipoprotein Lipase Gene in Pregancy-Induced Chylomicronemia: Possible Association with Apoplipoprotein E2 Isoform”,J. Lipid Research35: 1066-1075 (1994).
Ma et al., “Type III Hyperlipoproteinemia in Apo E2/2 Homozygotes: Possible Role of Mutations in the Lipoprotein Lipase Gene”,Circulation, Abstracts from the 66th Scientific Session of American Heart AssociationI-179 (1993). Abract 0953.
Reymer et al., “A Mutation (N291S) in the LPL Gene occurs with increased frequency in patients with Premature Atherosclerosis and hyperlipidemia”,Circulation90: Abst 0998 (1994).
Soria et al., “Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100”,Proc. Nat
Hayden Michael R.
Lewis Suzanne
Liu Guoquing
Ma Yuanhong
Oppedahl & Larson LLP
Priebe Scott D.
The University of British Columbia
LandOfFree
Gene therapy method for reducing risk of atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene therapy method for reducing risk of atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene therapy method for reducing risk of atherosclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3280784